California AB1887 mandates immediate prior authorization for FDA-approved drugs treating rare diseases.

California AB1887 requires health insurers and health care service plans to immediately approve prior authorization for FDA-approved drugs treating rare diseases within 30 days of an initial request. This applies if the drug is prescribed by a specialist who has determined it is medically necessary. The law defines a rare disease as one affecting fewer than 200,000 people in the United States. The requirement takes effect for policies and contracts issued, amended, or renewed on or after January 1, 2027.

California AB1887 mandates immediate prior authorization for FDA-approved drugs treating rare diseases.

California AB1887 requires health insurers and health care service plans to immediately approve prior authorization for FDA-approved drugs treating rare diseases within 30 days of an initial request. This applies if the drug is prescribed by a specialist who has determined it is medically necessary. The law defines a rare disease as one affecting fewer than 200,000 people in the United States. The requirement takes effect for policies and contracts issued, amended, or renewed on or after January 1, 2027.